Debate on SSRIs in Pregnancy Is Shifting: What the Latest Relapse vs Risk Evidence Shows

For decades, pregnant patients taking selective serotonin reuptake inhibitors (SSRIs) frequently received conflicting guidance, with many advised to abruptly taper or discontinue their medication upon confirming pregnancy. Recent epidemiological research and clinical analyses published in maternal-fetal medicine journals have shifted this consensus toward a more nuanced, individualized risk-benefit assessment.

Earlier studies associating SSRI exposure with congenital anomalies frequently failed to control for maternal psychiatric illness, concurrent substance use, chronic stress, and lifestyle factors. When contemporary studies account for these confounding variables, the absolute risk of major fetal malformations attributable directly to SSRI medications approaches baseline population rates.

A central finding driving the updated clinical guidance is the substantial risk of psychiatric relapse following medication cessation. Clinical trials and prospective registries demonstrate that patients who discontinue antidepressant therapy during pregnancy experience a relapse rate greater than 60%, compared to approximately 26% among individuals who maintain maintenance therapy (relative risk 2.30).

Maternal depressive relapse during gestation is not benign. Unmanaged depression and severe anxiety correlate with reduced prenatal visit compliance, poor nutritional intake, higher circulating cortisol and catecholamines, and an increased risk of preterm labor and low birth weight. Postpartum, unmanaged antenatal depression significantly increases the incidence of postpartum depression, postpartum anxiety, and impaired parent-infant attachment.

Clinicians evaluate two primary neonatal considerations when discussing SSRI continuation: persistent pulmonary hypertension of the newborn (PPHN) and neonatal behavioral adaptation syndrome (NBAS).

Large population-based cohort studies indicate that while the relative risk of PPHN may show a modest increase with late-trimester SSRI exposure, the absolute risk remains low (approximately 3 to 4 cases per 1,000 live births compared to a baseline of 1 to 2 per 1,000).

Neonatal behavioral adaptation syndrome occurs in approximately 20% to 30% of infants exposed to SSRIs near term. Symptoms are typically mild, transient, and self-limiting, presenting within the first 48 to 72 hours as jitteriness, mild respiratory irregularity, or altered sleep patterns. Hospital maternity units, including those staffed by Certified Nurse-Midwives across Arizona, routinely monitor newborns for these signs without requiring separation from the parent.

In Arizona, Certified Nurse-Midwives are licensed as independent Advanced Practice Registered Nurses (APRNs) with full, unrestricted prescriptive authority (Schedule II through V medications). CNMs regularly screen for perinatal mood and anxiety disorders during routine prenatal and postpartum visits.

When managing mental health in pregnancy, CNMs utilize evidence-based screening tools like the Edinburgh Postnatal Depression Scale (EPDS) and PHQ-9. Midwives initiate, titrate, or maintain SSRI pharmacotherapy while coordinating multidisciplinary care with perinatal psychiatrists, licensed counselors, and consulting OB/GYN physicians as needed.

Instead of applying blanket rules, maternity care teams utilize structured shared decision-making frameworks that weigh individual psychiatric history against potential infant effects. Key considerations include:

1. Patient psychiatric trajectory: Frequency, severity, and duration of past depressive or anxious episodes, including any history of hospitalization, self-harm, or severe functional impairment.

2. Medication stability: The specific molecule and dosage that achieved clinical remission prior to conception.

3. Non-pharmacological adjuncts: Incorporating cognitive behavioral therapy (CBT), interpersonal psychotherapy, physical activity, and social support structures.

4. Postpartum safety planning: Establishing early postpartum follow-up appointments (at 1, 2, and 6 weeks) and monitoring plans with partners and family members.